| APLS Stock | | | USD 31.91 1.14 3.70% |
President
Meredith Kaya is Investor President of Apellis Pharmaceuticals
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.7 in 2024.
Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals'
Other Current Assets are comparatively stable compared to the past year.
Net Tangible Assets is likely to gain to about 205.1
M in 2024, whereas
Non Current Assets Total are likely to drop slightly above 18.2
M in 2024.
Apellis Pharmaceuticals currently holds 110.93
M in liabilities with Debt to Equity
(D/E) ratio of 0.63, which is about average as compared to similar companies. Apellis Pharmaceuticals has a current ratio of 7.42, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Apellis Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age |
| John McKew | Lumos Pharma | 60 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. Apellis Pharmaceuticals (APLS) is traded on NASDAQ Exchange in USA. It is located in 100 Fifth Avenue, Waltham, MA, United States, 02451 and employs 702 people. Apellis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | |
| Cedric MD, President, CoFounder | |
| Meredith Kaya, Investor President | |
| Adam Townsend, Chief Commercial Officer | |
| James CPA, Corporate VP | |
| Karen Lewis, Chief Officer | |
| Nur Nicholson, Chief Officer | |
| JD Esq, General Counsel | |
| MBA JD, CoFounder Director | |
| Pr MD, Head Board | |
| David Acheson, Senior Commercial | |
| Lukas MD, Chief Officer | |
| Mark Delong, Chief Officer | |
| Federico MD, CoFounder Officer | |
| Victoria Brown, Senior President | |
| Pascal Deschatelets, CoFounder Officer | |
| Caroline MD, Chief Officer | |
| Jeffrey Eisele, Chief Officer | |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to
measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.